Research Article

Modulation of Colorectal Cancer Risk by Polymorphisms in 51Gln/His, 64Ile/Val, and 148Asp/Glu of APEX Gene; 23Gly/Ala of XPA Gene; and 689Ser/Arg of ERCC4 Gene

Table 8

Analysis of correlation of selected polymorphisms with the state of tumor according to classification of American Joint Committee on Cancer.

51Gln/His polymorphism of APEX gene
GenotypePatients ()II° versus I°III° + IV° versus I°III° + IV° versus II°
II°III°IV°OR (95% CI)OR (95% CI)OR (95% CI)
Gln/Gln24211951 (ref)1 (ref)1 (ref)
Gln/His57944871.885 (0.963–3.690)0.0620.965 (0.491–1.898)0.9200.512 (0.261–1.004)0.049
His/His1915200.902 (0.369–2.209)0.823

64Ile/Val polymorphism of APEX
GenotypePatients ()II° versus I°III° + IV° versus I°III° + IV° versus II°
II°III°IV°OR (95% CI)OR (95% CI)OR (95% CI)
Ile/Ile41321911 (ref)1 (ref)1 (ref)
Ile/Val64512851.021 (0.566–1.843)1.0001.057 (0.536–2.086)0.8621.035 (0.509–2.105)0.920
Val/Val33171420.660 (0.313–1.391)0.2730.994 (0.446–2.215)1.0001.506 (0.623–3.638)0.362

148Asp/Glu polymorphism of APEX
GenotypePatients ()II° versus I°III° + IV° versus I°III° + IV° versus II°
II°III°IV°OR (95% CI)OR (95% CI)OR (95% CI)
Asp/Asp2917501 (ref)1 (ref)1 (ref)
Asp/Glu98133512.315 (1.205–4.449)0.01
Glu/Glu165000.533 (0.166–1.716)0.288

23Gly/Ala polymorphism of XPA gene
GenotypePatients ()II° versus I°III° + IV° versus I°III° + IV° versus II°
II°III°IV°OR (95% CI)OR (95% CI)OR (95% CI)
Gly/Gly179501 (ref)1 (ref)1 (ref)
Gly/Ala87165923.582 (1.533–8.370)0.002
Ala/Ala115000.859 (0.227–3.248)0.823

689Ser/Arg polymorphism of ERCC4
GenotypePatients ()II° versus I°III° + IV° versus I°III° + IV° versus II°
II°III°IV°OR (95% CI)OR (95% CI)OR (95% CI)
Ser/Ser4931941 (ref)1 (ref)1 (ref)
Ser/Arg83521640.990 (0.561–1.747)1.0000.908 (0.415–1.986)0.8060.795 (0.356–1.776)0.578
Arg/Arg3224321.186 (0.592–2.374)0.6320.589 (0.192–1.811)0.3510.431 (0.137–1.352)0.143

Values set in italics denote statistical significance.